3661 related articles for article (PubMed ID: 21330184)
1. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
2. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed nanovehicles to overcome cancer chemoresistance.
Livney YD; Assaraf YG
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1716-30. PubMed ID: 23954781
[TBL] [Abstract][Full Text] [Related]
4. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
5. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
Gillet JP; Gottesman MM
Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109
[No Abstract] [Full Text] [Related]
6. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance in cancer: its mechanism and its modulation.
Pauwels EK; Erba P; Mariani G; Gomes CM
Drug News Perspect; 2007; 20(6):371-7. PubMed ID: 17925891
[TBL] [Abstract][Full Text] [Related]
8. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
Xue X; Liang XJ
Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
[TBL] [Abstract][Full Text] [Related]
9. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
10. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
12. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
Chen JN; Shen Q; Li SS
Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
[TBL] [Abstract][Full Text] [Related]
13. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
14. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.
Colabufo NA; Contino M; Berardi F; Perrone R; Panaro MA; Cianciulli A; Mitolo V; Azzariti A; Quatrale A; Paradiso A
Toxicol In Vitro; 2011 Feb; 25(1):222-30. PubMed ID: 21078380
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review.
Liu FS
Taiwan J Obstet Gynecol; 2009 Sep; 48(3):239-44. PubMed ID: 19797012
[TBL] [Abstract][Full Text] [Related]
16. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
Coley HM
Methods Mol Biol; 2010; 596():341-58. PubMed ID: 19949931
[TBL] [Abstract][Full Text] [Related]
17. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
Kibria G; Hatakeyama H; Harashima H
Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
19. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
Wang J; Tao X; Zhang Y; Wei D; Ren Y
Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
[TBL] [Abstract][Full Text] [Related]
20. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
Yadav S; van Vlerken LE; Little SR; Amiji MM
Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
